Reply to thread

It is clear that   Sustol won't be able to compete against cheap, generic Aloxi unless the FDA allows a prescribing label which includes a claim for the prevention of delayed-onset CINV in patients undergoing highly emetogenic chemotherapy. That's the magical, highly desirable fourth bucket in the CINV treatment market and what Heron must be trying to hold out for!